PITTSBURGH, Aug. 25, 2014 /PRNewswire/ -- Mylan Specialty,
the fully integrated specialty pharmaceutical business of Mylan
Inc. (NASDAQ: MYL), and pro football player and EpiPen®
(epinephrine) Auto-Injector spokesperson Adrian Peterson today announced the three
winners of the Ready2Go™ MVP Draft, a nationwide
search to find kids who have potentially life-threatening (severe)
allergies and are prepared to respond should a life-threatening
allergic reaction (anaphylaxis) occur.
To visit the multimedia assets associated with this release,
please click:
http://www.multivu.com/players/English/7162231-mylan-ready2go-mvp-draft-anaphylaxis-preparedness/
The winners recently joined Peterson to film an educational
video aimed at helping people recognize the signs and symptoms of
anaphylaxis and how to respond if it occurs. Results from a recent
survey* showed that 50% of parents of children with severe
allergies are concerned that they would not know what to do if
their child experienced anaphylaxis. These and other statistics
inspired the Ready2Go campaign and highlight the need for
further education.
"When I experienced anaphylaxis, I didn't know I had a
life-threatening allergy, what I was experiencing or how to
respond," said Peterson, who was shown how to administer an EpiPen
Auto-Injector into his outer thigh by his athletic trainer. "This
experience taught me that life happens, so I need to be prepared.
The Ready2Go campaign is my way of sharing what I learned
about being prepared and calling on other people to do the
same."
Being Ready2Go means avoiding your allergic triggers,
knowing the signs and symptoms of anaphylaxis, having access to two
EpiPen Auto-Injectors at all times and seeking emergency medical
care if anaphylaxis occurs.
The MVP Draft winners were selected based on the
educational and inspiring nature of the tips shared and the
creativity and originality of the entry. Submissions captured
important lessons including talking to restaurant staff and reading
labels to avoid allergic triggers. One winner from each of three
age groups was selected:
- Age group 5-9: Evan Johnson, 7
years old, Frisco, Texas
- Age group 10-13: Nathaniel
Campen, 10 years old, Rosemount,
Minn.
- Age group 14-18: Katherine
Schug, 14 years old, Scotch
Plains, N.J.
The Ready2Go educational video will debut on Ready2Go.com
this fall. The website features information about anaphylaxis,
Peterson's personal experience with severe allergies, and
information about the EpiPen Auto-Injector, including important
safety information and prescribing and patient information.
Adrian Peterson is a paid
spokesperson of Mylan Specialty.
About Anaphylaxis
Anaphylaxis is a life-threatening
allergic reaction that has many possible triggers, occurs quickly,
without warning, and must be treated immediately with epinephrine.
Symptoms may include hives or redness of the skin, tightness in the
throat, nausea, dizziness, breathing problems, a decrease in blood
pressure and/or fainting. Anaphylaxis can be caused by triggers,
such as food, stinging and biting insects, medicines, latex or even
exercise. While symptoms of an allergic reaction vary from person
to person, reactions can quickly progress to become
life-threatening.
An epinephrine auto-injector, such as EpiPen Auto-Injector,
should be given at the first sign of anaphylaxis, followed by
seeking immediate emergency medical care. Delays in epinephrine
administration have been associated with negative health
consequences, even possibly death. Antihistamines are useful for
treating hives or other skin symptoms but they do not treat the
life-threatening symptoms of anaphylaxis.
Indications
EpiPen® (epinephrine) 0.3 mg
and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are
for the emergency treatment of life-threatening allergic reactions
(anaphylaxis) caused by allergens, exercise, or unknown triggers;
and for people who are at increased risk for these reactions.
EpiPen and EpiPen Jr are intended for immediate self administration
as emergency supportive therapy only. Seek immediate emergency
medical treatment after use.
Important Safety Information
EpiPen Auto-Injectors
contain a single dose of epinephrine, which you inject into your
outer thigh. DO NOT INJECT INTO YOUR VEIN, BUTTOCK, FINGERS, TOES,
HANDS OR FEET. In case of accidental injection, please seek
immediate medical treatment. Epinephrine should be used with
caution if you have heart disease or are taking certain medicines
that can cause heart-related (cardiac) symptoms.
Tell your doctor if you have certain medical conditions such as
asthma, depression, thyroid disease, Parkinson's disease, diabetes,
high blood pressure and heart disease, have any other medical
conditions, are pregnant or plan to become pregnant, or are
breastfeeding or plan to breastfeed. Be sure to also tell your
doctor all the medicines you take, especially medicines for asthma.
If you have certain medical conditions, or take certain
medicines, your condition may get worse or you may have longer
lasting side effects when you take the EpiPen or EpiPen Jr
Auto-Injector.
The most common side effects may include increase in heart rate,
stronger or irregular heartbeat, sweating, nausea and vomiting,
difficulty breathing, paleness, dizziness, weakness or shakiness,
headache, apprehension, nervousness or anxiety. These side effects
usually go away quickly, especially if you rest.
Talk to your healthcare professional to see if EpiPen or EpiPen
Jr Auto-Injector is right for you.
Please click here for full Prescribing Information.
Please click here for Patient Information.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
Survey Methodology
*The survey was conducted online
by The Harris Poll on behalf of Mylan Specialty L.P. within
the United States between
March 10 - 28, 2014 among 509 U.S.
adults aged 18 and up who have been diagnosed with an allergy to
food, venom, or latex ("patients") and 515 U.S. adults who are the
parent or guardian of a child under 18 diagnosed with an allergy to
food, venom, or latex ("parents"). Results from the study were
weighted as needed for age, gender, race/ethnicity, education,
region, household income, parental status, and propensity to
be online to align them with their actual proportions in the
population.
About Nielsen & The Harris Poll
On February 3, 2014, Nielsen acquired Harris
Interactive and The Harris Poll. Nielsen Holdings N.V. (NYSE: NLSN)
is a global information and measurement company with leading market
positions in marketing and consumer information, television and
other media measurement, online intelligence and mobile
measurement. Nielsen has a presence in approximately 100 countries,
with headquarters in New York, USA
and Diemen, the Netherlands. For
more information, visit www.nielsen.com.
About EpiPen® Auto-Injector
EpiPen® (epinephrine) and EpiPen Jr®
(epinephrine) Auto-Injectors are used for the emergency treatment
of life-threatening allergic reactions. Each EpiPen
2-Pak® and EpiPen Jr 2-Pak® contains two
single auto-injectors, instructions for use and a training device,
with no drug product or needle, to help patients become familiar
with the administration technique. EpiPen Auto-Injector should be
administered immediately at the first sign of an anaphylactic
reaction. EpiPen Auto-Injector is not a substitute for emergency
medical treatment. Patients should seek emergency medical
attention immediately following administration. EpiPen
Auto-Injector has been the No. 1 prescribed epinephrine
auto-injector for more than 25 years and has three-step simple
instructions for use. For more information about EpiPen
Auto-Injector, please visit www.EpiPen.com.
About Mylan Specialty
Mylan Specialty, a subsidiary of
Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company
focused on the development, manufacturing and marketing of
prescription drug products for the treatment of respiratory
diseases, life-threatening allergic reactions and psychiatric
disorders. For more information, please visit
mylanspecialty.com.
About Mylan
Mylan is a global pharmaceutical company
committed to setting new standards in health care. Working together
around the world to provide 7 billion people access to high quality
medicine, we innovate to satisfy unmet needs; make reliability and
service excellence a habit; do what's right, not what's easy; and
impact the future through passionate global leadership. We offer a
growing portfolio of more than 1,300 generic pharmaceuticals and
several brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
EpiPen®, EpiPen Jr®, EpiPen
2-Pak® and EpiPen Jr 2-Pak® are registered
trademarks of Mylan Inc. licensed exclusively to its wholly-owned
subsidiary, Mylan Specialty L.P.
Ready2Go™ is a trademark of Mylan
Inc.
© 2014 Mylan Specialty L.P. All rights reserved.
EPI-2014-0721.
To visit the multimedia assets associated with this release,
please click:
http://www.multivu.com/players/English/7162231-mylan-ready2go-mvp-draft-anaphylaxis-preparedness/
SOURCE Mylan Specialty L.P.